The US and Japanese patents cover the company’s whole slide imaging and analysis platform, which simultaneously measures tumor, immune, and stromal cells, processes, and biomarkers on a single specimen.
Cernostics CEO Mike Hoerres said these patents are an important part of company’s intellectual property strategy and provide its technology platform with long-term market exclusivity.
"No other diagnostics technology can replicate our tissue systems biology approach to anatomic pathology – the TissueCypher platform will bring unique, actionable information to the healthcare community," Hoerres added.
Cernostics is currently collaborating with top healthcare organizations including Geisinger Health System, the University of Pittsburgh, and the University of Pennsylvania to market TissueCypher.
